|
www.aurobindo.com |
|
|
|
|
Aurobindo Pharma Unveils New Corporate Identity |
|
One of India’s Leading
pharmaceutical Company all set to become a global powerhouse |
|
|
Aurobindo Pharma Ltd, one of
India’s leading pharmaceutical companies, today
unveiled its new Logo and corporate Identity at
a ceremony in Hyderabad. |
|
Speaking on the occasion, Mr. P.V.
Ramaprasad Reddy, Chairman, Aurobindo Pharma Ltd
said, “We
are proud to introduce our new corporate
identity. Our new logo is intended to
better reflect the value and personality of the
Group as we expand - speed, simplicity and
synergy. It also
shows that we are as strong and
progressive as ever, and that we are constantly
increasing our knowledge and skills better to
serve our clients.
The new identity, dynamism and
excellence will bring a sense of rejuvenation
and growth to the company and its employees”. |
|
He further added “Our vision is
to become a leading provider of generic
pharmaceuticals from Asia by 2015.” Our
immediate goal is to surpass US$ 1 bio landmark
in two to three years. We have just crossed the
US$ 500 mio landmark. |
|
Aurobindo has come a long way in
the last 20 years. Today we are a fully
integrated pharmaceutical company in the global
arena exporting pharmaceuticals to over 100
countries. Aurobindo has built a robust product
portfolio to capture sizeable market share in
the world through rapid filing of process
patents, DMFs and ANDAs. |
|
Today Aurobindo is one amongst
the top in the world in terms of DMF filings in
USA, a major landmark to reflect the creation of
intellectual property. Six therapeutic areas and
seven formulation technology platforms are
driving the growth by quantums. Aurobindo is
an equal opportunity employer and has over 30
nationalities working across the globe. |
|
Aurobindo is closer to customers
with several subsidiaries and branches
established across and is local in each country
with significant local people manning the
operations. Aurobindo’s targeted manufacturing
infrastructure is approved by all leading
regulatory agencies in the world and the
formulations are accepted across the world – for
example, every leading
wholesaler/chain/distributor is a client of
Aurobindo. |
|
Our new corporate logo reflects
our commitment to speed, simplicity and
leadership. Artistic lines intersect to make up
our initials, which interpret that we are moving
upwards at a rapid pace and designed to convey
our global coverage. The logo signifies and
conveys what the company stands for, in terms of
its commitment to customers and brand values.
The new corporate identity reflects the Group’s
value based business ethics, transparency of
operations and excellence in corporate
governance. We also believe that this new look
is in tune with the enormous opportunities that
lay ahead of us, which will enable us to become
a global powerhouse!! |
|
The new identity comes at a time
when the group is preparing to announce a series
of exciting business initiatives. Aurobindo
Pharma one of the leading pharmaceutical
companies in India with 14 manufacturing sites
across the world, over 6000 employees, 22
overseas subsidiaries, half-a-billion dollar
revenue is set to reflect its true image. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company has
received approvals for most of the targeted API
and formulation facilities from leading
regulatory agencies like US FDA, UK MHRA, WHO,
Health Canada, MCC South Africa.
The company’s robust product
portfolio is spread over 6 major
therapeutic/product areas encompassing
Antibiotics, Anti-Retrovirals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics. The
formulation portfolio is built on six technology
platforms such as immediate release generics,
SR/CR generics, orally disintegrating/mouth
dissolving generics, combination products,
Sterile/Lyophilized generics and liquids/dry
syrups.
Aurobindo has filed over 100 DMFs
and 90 ANDAs for the USA market alone in
addition to filings in other countries. The pace
of filings is matched by rapid product approvals
from various markets. Till date Aurobindo
received 42 ANDA approvals (both final and
tentative) from US alone. Aurobindo operates in
over 100 countries and markets over 180 APIs and
250 formulations. |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 6672 5000
Mobile 0 98486 67906
Email : ir@aurobindo.com |
|
|
|
|
|
|
|
|
|
PRESS
ROOM
